Oragenics Provides Update on Phase IIa Trial for Concussion Treatment and CNS Expansion Plans

Oragenics Inc. (NYSE American: OGEN) provided a shareholder update on Wednesday, highlighting significant progress in its Phase IIa clinical trial of ONP-002 for concussion and mild traumatic brain injury (mTBI). The trial, being conducted in Australia, is actively enrolling and dosing patients across multiple sites. The company also outlined plans to advance U.S. regulatory preparations, including a Type C FDA meeting request expected in the second quarter of 2026 and an Investigational New Drug (IND) submission targeted by year-end 2026.

In addition to the clinical updates, Oragenics disclosed a letter of intent to pursue licensing of a complementary central nervous system (CNS)-related medical device, signaling a strategic expansion beyond its lead candidate. The company reported a cash balance of $6.1 million as of March 31, 2026, which is expected to fund operations into the third quarter of 2026. The full press release is available at https://ibn.fm/tEk2C.

ONP-002 is a potential first-in-class treatment for concussion and mTBI, delivered via Oragenics' proprietary intranasal delivery technology. This platform has potential applications across multiple neurological conditions, including Parkinson's disease, Alzheimer's disease, PTSD, and anxiety disorders. The ongoing Phase IIa trial in Australia is a critical step toward demonstrating safety and efficacy, with U.S. Phase 2b trials planned to follow.

The company's strategic expansion into CNS-related medical devices, as indicated by the letter of intent, could diversify its pipeline and address additional unmet needs in neurological care. Oragenics is committed to developing innovative therapies that target significant gaps in current treatment options for brain injuries and other CNS disorders.

Investors can find the latest news and updates regarding OGEN in the company's newsroom at https://ibn.fm/OGEN. Oragenics, based in the United States, is a clinical-stage biotechnology company focused on brain-targeted therapeutics.